Catalog No.
DHB86950
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG
Target
Bispecific, HER1, Receptor tyrosine-protein kinase erbB-1, Proto-oncogene c-ErbB-1, Epidermal growth factor receptor, EGFR, ERBB1, ERBB, CD16a, CD16A, FCGR3A, Fc-gamma RIII-alpha, FcRIIIa, IgG Fc receptor III-2, Low affinity immunoglobulin gamma Fc region receptor III-A, IGFR3, CD16a antigen, Fc-gamma RIII, FCGR3, Fc-gamma RIIIa, FCG3, FcRIII, FcR-10
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P00533 & P08637
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
AFM24, AFM-24, AFM 24
Clone ID
AFM24
PI3K-dependent GAB1/Erk phosphorylation renders head and neck squamous cell carcinoma sensitive to PI3Kα inhibitors., PMID:40533463
N6-methyladenosine-modified GPX2 impacts cancer cell stemness and TKI resistance through regulating of redox metabolism., PMID:40533443
"Partial Nephrectomy with Veriset: A Renorrhaphy-Less Approach"., PMID:40533087
Effects of Ganoderma spent substrate containing with polysaccharides and triterpenoids on the growth performance, antioxidant capacity and immunity level of chickens., PMID:40532998
Identifying the genomic landscape of EGFR-mutant lung cancers with CNS metastases., PMID:40532851
SGLT-2 inhibitors: a deeper dive into their renal protective properties beyond glycemic control and proteinuria reduction., PMID:40532669
Safety and efficacy of perioperative dual PD-1 and HER2 blockade in HER2-positive gastric cancer., PMID:40532664
Metabolic control of glycosylation forms for establishing glycan-dependent protein interaction networks., PMID:40531880
Design, synthesis and anti-tumor activity of oleanolic acid derivatives targeting EGFR., PMID:40531475
Local cranial radiation combined with third-generation tyrosine kinase inhibitors improve leptomeningeal metastasis disease-free survival in patients with EGFR-mutated non-small cell lung cancer and brain metastasis., PMID:40531436
HEY1 promotes the development and metastasis of osteosarcoma through CD44/EGFR/FAK pathway., PMID:40531089
PD-1/PD-L1 inhibitors plus chemotherapy versus chemotherapy alone for TKIs-resistant, EGFR-Mutant, advanced non-small-cell lung cancer: a phase 3 RCTs based meta-analysis., PMID:40531080
TRPV3 calcium channel at the crossroads of epidermal differentiation and inflammation., PMID:40530577
Karyomegalic interstitial nephritis: A case series and review of the literature on genetic insights and clinical challenges., PMID:40529986
Integrated pan-cancer analysis of ADM's role in prognosis, immune modulation and resistance., PMID:40529377
Angio-associated migratory cell protein promotes colorectal cancer progression by enhancing phosphoglycerate kinase 1 phosphorylation., PMID:40529105
From planning to prognosis: predicting renal function after minimally-invasive partial nephrectomy with artificial intelligence., PMID:40528776
Growth Inhibition Activity Assessment of γ-Lactam-Containing Chemicals in Cultured MCF-7 Cells and Xenografted Chick Embryos., PMID:40528652
Real-World Survival Outcomes of Patients With High PD-L1 Advanced NSCLC Who Received Chemoimmunotherapy Versus Immunotherapy., PMID:40528544
EGFR-TKI combination treatment for NSCLC with EGFR-sensitive mutation., PMID:40528340
Impact of Bariatric Metabolic Surgery on Cardiovascular, Kidney, and Mortality Outcomes Among Adults with Obesity and Chronic Kidney Disease Across Different Time Frames., PMID:40528074
Clinicopathological features and renal outcomes in patients with IgA nephropathy secondary to psoriasis., PMID:40528031
EGFRvIII-positive glioblastoma contributes to immune escape and malignant progression via the c-Fos-MDK-LRP1 axis., PMID:40527884
Prevalence and characteristics of lung cancer in families harboring Pathogenic Germline Variants in cancer predisposing genes: A 20-year retrospective analysis., PMID:40527197
Immune Subtyping Identifies Patients With Hormone Receptor-Positive Early-Stage Breast Cancer Who Respond to Neoadjuvant Immunotherapy (IO): Results From Five IO Arms of the I-SPY2 Trial., PMID:40526879
Amphiregulin contributes to neuropathic pain by enhancing glycolysis that stimulates histone lactylation in sensory neurons., PMID:40526786
Multitarget inhibition of CDK2, EGFR, and tubulin by phenylindole derivatives: Insights from 3D-QSAR, molecular docking, and dynamics for cancer therapy., PMID:40526618
Use of eGFR Slope Thresholds as End Point Components in a Kidney Disease Progression Hierarchical Composite End Point., PMID:40526444
Hemorrhagic complications after ultrasound-guided percutaneous native renal biopsy: a prediction model based on clinical and ultrasonographic features under a nest case-control design., PMID:40526135
Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment., PMID:40526090
Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights., PMID:40526089
Real-world treatment patterns and outcomes of patients with hormone receptor-positive/HER2-low metastatic breast cancer treated with chemotherapy., PMID:40525913
Altered fecal microbial and metabolic profiles reveal potential mechanisms underlying anemia in patients with chronic renal failure., PMID:40525868
Spatial Transcriptomic Landscape of Canine Oral Squamous Cell Carcinoma., PMID:40525754
Comparison of Intrapatient Variability of IR-Tacrolimus Versus LCP-Tacrolimus in a Cohort of Lung Transplant Recipients., PMID:40525559
Development and Verification of a Physiologically Based Pharmacokinetic Model of Furmonertinib and Its Main Metabolite for Drug-Drug Interaction Predictions., PMID:40525261
Efficacy and safety of telitacicept in IgA nephropathy: real-world study outcomes., PMID:40525115
Associations Between Renal Dysfunction Subtypes and Vertebral Fracture in Patients with Type 2 Diabetes: A Longitudinal Study., PMID:40524869
Crosstalk Between EGFR and Integrin Affects Invasion and Proliferation of Gastric Cancer Cell Line, SGC7901 [Retraction]., PMID:40524861
Adjuvant pembrolizumab therapy for completely resected stage I lung adenocarcinoma with micropapillary or solid histological subtypes: a single-center, single-arm, phase 2 trial., PMID:40524802
Registry-Based Living Kidney Donor Follow-Up in Australia: An ANZLKD Analysis 2003-2021., PMID:40524554
Safety and Efficacy of the First Subcutaneous ICI, Envafolimab, in the Treatment of Advanced Lung Cancer Patients: A Real-World Study., PMID:40524516
Two-dimensional analysis of plasma-derived extracellular vesicles to determine the HER2 status in breast cancer patients., PMID:40524202
Clinical Efficacy and Safety of Apatinib Combined with Irinotecan in HER2-negative Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma after First-Line Treatment Failure: A Single-Arm, Single-Center Retrospective Study., PMID:40524072
Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer., PMID:40524071
Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation., PMID:40523897
Unveiling predisposing factors for cefepime-induced neurotoxicity: A systematic review and meta-analysis., PMID:40523836
Dysfunctional Pericellular Hyaluronan Deposition Contributes to Attenuated CD44/EGFR Co-localization and Impaired Myofibroblast Differentiation in Chronic Wound Fibroblasts., PMID:40523596
Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial., PMID:40523368
Design, Synthesis, and Anticancer Evaluation of Novel 6-Alkynylated Harmine Derivatives., PMID:40522774
For research use only. Not for human or drug use.
